Replies to post #798930 on NorthWest Biotherapeutics Inc (NWBO)

[ilovetech]

I know I'm bouncing back and forth here, but that is true. The latest PR referenced scaling requirements, NOT approval.
I would go even further by saying an intermediate approval may have provided the company with the confidence needed to pull the latest triggers. The MHRA has to know how under pressure a pre revenue company is to demand a 6 month build out, without giving anything back for it. The idea that the MHRA couldn't care less, and think, "meh, let them eat cake for another six months.." is also not reasonable to believe.



NWBio has always consistently said that they will start meeting patient demand by manufacturing DCVax-L in the Class B suite at the Sawston facility after initial approval.

[WideEyed]

ATLnsider,

After installation of first Grade C suite, what do you think the Sawston full capacity becomes? The existing Grade B suite full capacity is over $2 billion. Today’s PR says “The Company anticipates that the manufacturing capacity of the first Grade C suite will more than double the aggregate capacity of the existing Grade B manufacturing suites combined.” Does this mean the Grade C suite capacity is $4 billion, so the new total capacity is $2 billion + $4 billion = $6 billion ? Or when the PR says more than double existing Grade B, does that really mean double the total capacity to $4 billion? I could see it either way. What do you think?